Skip to main content

Table 3 List of detected positron emission tomography agents

From: Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database

Positron Emission Tomography Agent as Stated in ClinicalTrials.gov Radionuclid IUPAC name of the carrier or other relevant source Number of trials
Acetate (11C)a Acetate 22
Choline (11C)a 2-Hydroxy-N,N,N-trimethylethan-1-aminium 16
Choline (18F)a 2-Hydroxy-N,N,N-trimethylethan-1-aminium 37
Choline NOSa 2-Hydroxy-N,N,N-trimethylethan-1-aminium 7
Citrate (68Ga) 2-Hydroxypropane-1,2,3-tricarboxylic acid 1
DFO-huJ591 (89Zr) Recombinant humanized monoclonal antibody J591 conjugated to chelator desferrioxamine B 1
DFO-MSTP2109A (89Zr) Desferrioxamine - DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells 1
DHT (18F)a (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one 3
DOTA-Bombesin (68Ga) 68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl. 1
DOTATET (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (also known as DOTA) 1
FAZA (18F) Nitroimidazole nucleoside analogue 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole (FAZA) 2
FDG (18F)a 2-Deoxy-2-[18F]fluoroglucose 15
FLT (18F) 1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione 1
Fluciclovine (18F) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid 13
Fluciclovine (NOS) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid 1
Fluorocholine (18F) Fluoromethyl-(2-hydroxyethyl)-dimethylazanium;chloride 1
FMAU (18F) 2′-deoxy-2′-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU [18F-FMAU]), 3
MeAIB (NOS)a 2-methyl-2-(methylamino)propanoic acid 1
Methionine (11C)a (2S)-2-amino-4-methylsulfanylbutanoic acid 3
MISO (18F) 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol 1
NaF (18F)a Sodium;fluoride 20
NODAGA-MJ9 (Ga-68)a 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA) 1
NOTA-BBN-RGD (68Ga) 1,4,7-triazacyclononanetriacetic acid (NOTA), Arg-Gly-Asp (RGD) and bombesin (BBN) 1
P15–041 (68Ga) Unknown 1
PACAP (64Cu) Pituitary adenylate cyclase-activating peptide 2
Peripheral Benzodiazepine Receptor-28 (11C) Peripheral Benzodiazepine Receptor-28 1
PSMA DCFPyL (18F)a N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine ([18F]DCFBC) 21
PSMA (68Ga) Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I 15
PSMA (89Zr) Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I 2
PSMA CTT 1057 (NOS) Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology firm that will develop the agent, CTT1057. CTT1057 is a small molecule that homes in and binds irreversibly to prostate specific membrane antigen (PSMA) 1
PSMA DCFBC (18F) (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC) 4
PSMA Df-IAB2M (89Zr) Zr-89-desferrioxamine-IAB2M 1
RM2 (68Ga) 68Ga-RM2 stands for Galium-68 labeled DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 3
Sodium Fluoride (18F) Sodium Fluoride 1
uPAR NOTA (68Ga) Urokinase Plasminogen Activator Receptor 1
  1. aAgent was an optional or was compared to other agent in more than one trial